​

AbCellera Biologics Stock (NASDAQ:ABCL)

ForecastRevenueOwnershipFinancialsChartTranscripts
AbCellera Biologics by TradingView

Previous Close

$3.65

52W Range

$1.89 - $6.51

50D Avg

$3.64

200D Avg

$4.05

Market Cap

$1.05B

Avg Vol (3M)

$4.23M

Beta

0.87

Div Yield

-

ABCL Company Profile

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

596

IPO Date

Dec 11, 2020

Website

ABCL Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Milestone Payments$1.00M$1.50M$1.50M
License$46.92M$1.05M$969.00K
Research Fees$27.21M$26.28M$35.56M
Royalty---

Fiscal year ends in Dec 25 | Currency in USD

ABCL Financial Summary

Dec 25Dec 24Dec 23
Revenue$75.13M$28.83M$38.02M
Operating Income$-217.10M$-314.77M$-237.21M
Net Income$-146.41M$-162.86M$-146.40M
EBITDA$-155.42M$-204.15M$-192.16M
Basic EPS$-0.49$-0.55$-0.51
Diluted EPS$-0.49$-0.55$-0.51

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Feb 24, 26 | 5:00 PM
Q3 25Nov 07, 25 | 5:00 PM
Q2 25Aug 07, 25 | 5:00 PM

Peer Comparison

TickerCompany
PHVSPharvaris N.V.
SIONSionna Therapeutics, Inc.
NUVBNuvation Bio Inc.
XERSXeris Biopharma Holdings, Inc.
SYRESpyre Therapeutics, Inc.
BHVNBiohaven Ltd.
CLDXCelldex Therapeutics, Inc.
VERAVera Therapeutics, Inc.
JANXJanux Therapeutics, Inc.
IMNMImmunome, Inc.